Clinical trial · Interventional
Safety Study Of SNX-5422 To Treat Solid Tumor Cancers And Lymphomas
Phase 1 Study Of SNX-5422 Mesylate In Adults With Refractory Solid Tumor Malignancies And Lymphomas
NCT00647764CI-TRIAL-00006944completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Hsp90 is a chemical in the body that is involved in promotion of cancer. SNX-5422 is an experimental drug that blocks Hsp90. It is being evaluated for safety and efficacy in patients with cancer.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| SNX-5422 Mesylate Hsp90 inhibitor | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Single Arm
- interventionNames
- Drug: SNX-5422 Mesylate Hsp90 inhibitor
Primary outcomes (1)
- measure
- MTD, safety and toxicity
- timeFrame
- continuous
Secondary outcomes (2)
- measure
- pharmacokinetic profile of SNX-5422
- timeFrame
- first cycle
- measure
- tumor response measured by X-rays or scans
- timeFrame
- after every 2 cycles
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Solid tumors or lymphoid malignancies refractory to standard therapy * measurable disease * recovery to Grade \< 1 toxicity due to prior adverse event or chemotherapy * no chemotherapy within 4 weeks of entering study * Age \> 18 years * Karnofsy \>= 60% * Life expectancy \> 3 months * normal or adequate organ and marrow function Exclusion Criteria: * receiving other investigational agents * brain metastases * uncontrolled medical illness * HIV+ receiving combination antiretroviral therapy * significant GI disease
References
Publications (0)
Data not yet available
No reference posted for this study.